The short version of Reference standard fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-02-19. Anything still debated is marked as such rather than presented as settled.
Sporting authorities added GW501516 to prohibited lists after it appeared in athlete samples and online markets. The World Anti-Doping Agency classifies it as a hormone and metabolic modulator, and its use can lead to an anti-doping rule violation. Some early laboratory work suggested effects on fatty acid oxidation and endurance-related metabolism in animals, but those findings do not establish safe or effective use in people. Reports of adverse events in humans are scarce and often anecdotal, which complicates risk assessment.
Legal status varies by country. In some places, cardarine is controlled under medicines or psychoactive substances laws; in others, it may be sold with minimal oversight as a research chemical. Customs agencies have intercepted shipments, and several national health agencies have issued warnings about products marketed for bodybuilding or performance enhancement. The lack of a standardized pharmaceutical supply means identity, purity, and contamination levels can differ widely between samples. These factors make cardarine a regulatory and public health concern rather than a conventional prescription drug.
Cardarine is a common name for GW501516, a synthetic compound first described in the 1990s as a selective agonist of the peroxisome proliferator-activated receptor delta. It was studied in preclinical models for metabolic and cardiovascular conditions, but it has not been approved as a medicine in the United States, Europe, or other major jurisdictions. Retail products labeled as cardarine are generally research chemicals or supplements, not pharmaceutical formulations. Because human safety and efficacy data remain limited, regulatory agencies treat it as an unapproved substance rather than a therapeutic product.
Quality assessment for cardarine samples usually combines identity, purity, and impurity testing. Nuclear magnetic resonance spectroscopy and mass spectrometry can confirm molecular structure, while high-performance liquid chromatography estimates purity. Certificates of analysis from testing laboratories may list these results, but they do not establish safety or legality. In the absence of approved manufacturing, products sold online may contain the wrong compound, variable amounts, or unlisted contaminants. Independent verification is therefore central to analytical work and to interpreting any reported biological activity.
Laboratory detection of GW501516 commonly uses liquid chromatography coupled with tandem mass spectrometry. The method can identify the parent compound or its metabolites in urine and blood after sample cleanup. Protein precipitation, solid-phase extraction, or enzymatic hydrolysis may precede analysis, depending on the matrix. Reference standards are required for accurate quantification and confirmation. Because the compound is not approved, testing often occurs in anti-doping, forensic, or research settings rather than routine clinical care. Results are reported with limits of detection and quantification.
| Property | Value | Notes |
|---|---|---|
| IUPAC name | {4-[({4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl}methyl)sulfanyl]phenoxy}acetic acid | Systematic name for GW501516 |
| CAS Registry Number | 317318-70-0 | Unique identifier for the parent compound |
| Molecular formula | C21H18F3NO3S2 | Includes carbon, hydrogen, fluorine, nitrogen, oxygen, and sulfur |
| Molecular weight | 453.5 g/mol | Approximate value for the neutral form |
| Appearance | White to off-white powder | Typical description for purified laboratory material |
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
A common misconception is that cardarine has been proven safe for human use. In reality, human clinical data are limited, and long-term animal studies have raised concerns about cancer. Another misconception is that it is a supplement or vitamin-like compound. It is a synthetic research chemical with no approved medical indication. Scientific discussion often focuses on its mechanism and detection rather than therapeutic use. Regulatory and anti-doping literature treats it primarily as a prohibited substance.
Cardarine is explicitly prohibited by the World Anti-Doping Agency under the class of PPARδ agonists. Its presence in urine or blood samples can be detected using mass spectrometry-based methods, often liquid chromatography-tandem mass spectrometry. Athletes who test positive may face sanctions, including bans from competition. The compound is also regulated as a prescription-only or unapproved drug in many countries. Enforcement varies by jurisdiction, and some regions treat it as a controlled substance. Online sales may occur despite these restrictions, creating quality and legal risks.
Handling and quality assessment of cardarine reference material follow general laboratory practices for poorly characterized compounds. It typically appears as a white to off-white powder and is sparingly soluble in water but soluble in organic solvents such as dimethyl sulfoxide and ethanol. Storage recommendations usually specify a cool, dry, dark place, with long-term storage at low temperature and desiccation. Purity may be checked by high-performance liquid chromatography with ultraviolet detection, while identity is confirmed by mass spectrometry and nuclear magnetic resonance. No pharmacopeial monograph exists, so reported purity and stability depend on the supplier’s methods.
GW501516 acts as a selective agonist at PPARδ, a nuclear receptor that regulates transcription of genes involved in lipid handling and energy metabolism. Activation of PPARδ in preclinical models increases fatty acid oxidation, mitochondrial biogenesis, and exercise endurance in rodents. These effects have made the compound a subject of metabolic research and also a target for sport anti-doping rules. In humans, however, controlled studies are limited, and whether similar endurance or metabolic changes occur at tolerated exposures remains an open question. The receptor’s broad tissue distribution also means downstream effects may vary by organ and condition.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
Medical cannabis, or medical marijuana, refers to the use of herbal cannabis or its preparations to treat disease or improve symptoms. There is no single agreed-upon definition (e.g., cannabinoids derived from cannabis and synthetic cannabinoid analogs are also used). The rigorous scientific study of cannabis as a medicine has been hampered by production restrictions and by the fact that it is classified as an illegal drug by many governments. Evidence supports only a few approved uses of cannabinoids and most medical claims, such as efficacy for insomnia or acute pain, lack sufficient evidence; benefits, risks, and harm-reduction strategies should be evaluated before clinical recommendations of cannabis or cannabinoids. There is some evidence suggesting cannabis can be used to reduce nausea and vomiting during chemotherapy, to improve appetite in people with HIV/AIDS, or to treat chronic pain and muscle spasms. Evidence for its use for other medical applications is insufficient for drawing conclusions about safety or efficacy. There is evidence supporting the use of cannabis or its derivatives in the treatment of chemotherapy-induced nausea and vomiting, neuropathic pain, and multiple sclerosis. Lower levels of evidence support its use for AIDS wasting syndrome, epilepsy, rheumatoid arthritis, and glaucoma. The medical use of cannabis is legal only in a limited number of territories, including Belgium, Australia, the Netherlands, New Zealand, Spain, and many U.S. states.
Ronke Mojoyinola Olabisi (born 26 June 1976) is an associate professor of biomedical engineering at University of California, Irvine. She works on speciality of bone and human tissue. She is working with Mae Jemison on 100 Year Starship, an interdisciplinary initiative that is exploring the possibility of human interstellar travel.
Panda Express also operates in Aruba, Canada, El Salvador, Guatemala, Japan, Mexico, the Philippines, Saudi Arabia, South Korea, and the United Arab Emirates. The first location in Mexico opened in Mexico City in September 2011. In October 2013, the first Panda Express located in Canada opened on Hunt Club Road in Nepean, Ontario, but has since closed. The first location in Calgary was opened in October 2016. On May 26, 2014, it was reported by Arabian Business news that Panda Express would be opening a restaurant in the United Arab Emirates. The first Panda Express restaurant in the Middle East was opened in Dubai in November 2014. The first location in South Korea was opened in Seoul in September 2014 as a joint venture with Seoul-based SF Innovation Co. In July 2016, Panda Express opened its first location in Guatemala, in Guatemala City. In September 2017, Panda Express opened its first location on the Dutch Caribbean country of Aruba at the Queen Beatrix International Airport. Although it is unknown when Panda Express opened its first restaurant in Saudi Arabia, a second Panda Express in Saudi Arabia opened in Riyadh in January 2018. Both Saudi Arabian restaurants, as well as the ones in United Arab Emirates are operated by Gourmet Gulf. In July 2018, Panda Express entered El Salvador for the first time by opening two locations in the capital city of San Salvador.
Hood was born on October 10, 1938, in Missoula, Montana, to Thomas Edward Hood and Myrtle Evylan Wadsworth. and grew up in Shelby. His father was an electrical engineer, and his mother had a degree in home economics. Hood was one of four children, including a sister and two brothers, including a brother with Down syndrome. One of his grandfathers was a rancher and ran a summer geology camp for university students, which Hood attended as a high school student. Hood excelled in math and science, being one of forty students nationally to win a Westinghouse Science Talent Search. In addition, Hood played several high school sports and debate, the latter of which he would credit for his success in science communication later in his career.
=== Side effects === Side effects of alcohol and beta blockers include high blood pressure, dizziness, nausea, diarrhea, constipation, slow heartbeat, liver disease, cancer, dementia, and/or impotence or loss of sexual drive.
Sources: en.wikipedia.org
=== Novel genes === In general, genes without detectable homologs can be summarized under the term novel genes. These genes can also be called orphan genes, or — more precisely — species-/lineage-specific genes. The term de novo describes a specific subclass of novel genes, namely genes emerging from non-genic sequences. A key caveat is that orphan (taxonomically restricted) genes are heterogeneous in origin and age—lack of detectable homology can reflect multiple processes (including horizontal transfer, transposable element domestication, overprinting, or extreme divergence) and is not, by itself, evidence of de novo origin.
Deployment of such agents began to accelerate in late 2023 after OpenAI's "function-calling" API was made available, and especially after Anthropic's late 2024 introduction of Model Context Protocol (MCP), a standardised way for LLM agents to gain contextual awareness, and to act on the world by calling various external tools. The term "agentic" only began to be used with any frequency in 2024, popularised in part by researcher Andrew Ng.
In a complementary technique, peptide mass fingerprinting involves digestion of the native and modified protein with a protease such as trypsin. This will produce a set of peptides that can be analysed using a mass spectrometer. The peptide that changes in mass after reaction with the inhibitor will be the one that contains the site of modification.
A number of studies have shown that tobacco use is a significant factor in miscarriages among pregnant smokers, and that it contributes to a number of other threats to the health of the fetus such as low birth weight and pre-term birth. It slightly increases the risk of neural tube defects. Environmental tobacco smoke exposure and maternal smoking during pregnancy have been shown to cause lower infant birth weights.
Sources: en.wikipedia.org
No. Major drug regulators have not approved GW501516 for treating any medical condition. Products sold as cardarine are typically unapproved research chemicals or supplements, so their contents and safety are not assured.
It is prohibited by the World Anti-Doping Agency as a hormone and metabolic modulator. Athletes who test positive for GW501516 can face sanctions, including suspensions and loss of results.
Cardarine is a common or trade-style name, while GW501516 is the research code for the same chemical entity. Some sources also use Endurobol or GSK-516. The names refer to the same compound, not distinct drugs.
LC-MS/MS is common, often after sample cleanup. The assay targets GW501516 or its metabolites.